News Releases

Oct 24, 2026

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Oct 23, 2026

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Oct 02, 2026

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Sep 03, 2026

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Sep 02, 2026

Climb Bio to Present at Upcoming Investor Conferences

Aug 06, 2026

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates